drugset / Trial / NCT04616924
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung infection.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2023-08-28
- Completion
- 2023-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 158.3 mg | — |
| Subject | Clofazimine | Small molecule | 13.3 mg | — |
| Subject | Rifabutin | Small molecule | 40 mg | — |